Complete financial analysis of Zhejiang Huakang Pharmaceutical Co., Ltd. (605077.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Huakang Pharmaceutical Co., Ltd., a leading company in the Chemicals industry within the Basic Materials sector.
- Kian Shen Corporation (1525.TW) Income Statement Analysis – Financial Results
- Domain Holdings Australia Limited (DHGAF) Income Statement Analysis – Financial Results
- MAV Beauty Brands Inc. (MAV.TO) Income Statement Analysis – Financial Results
- Balady Poultry Trading Co. (9559.SR) Income Statement Analysis – Financial Results
- Limitless X Holdings Inc. (VYBE) Income Statement Analysis – Financial Results
Zhejiang Huakang Pharmaceutical Co., Ltd. (605077.SS)
About Zhejiang Huakang Pharmaceutical Co., Ltd.
Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols worldwide. Its products include xylitol, a polyol with close to sugar sweetness; sorbitol, a sugar alcohol being white crystal powder; maltitol, a sugar alcohol; xylose that is used in xylitol production; and L-arabinos, which can be used as sucrose replacement or additives. The company is based in Kaihua County, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.78B | 2.20B | 1.59B | 1.32B | 1.51B | 1.40B | 924.63M | 763.34M |
| Cost of Revenue | 2.11B | 1.70B | 1.23B | 858.18M | 999.41M | 1.02B | 698.04M | 600.84M |
| Gross Profit | 672.92M | 504.68M | 367.13M | 461.47M | 511.44M | 378.53M | 226.59M | 162.50M |
| Gross Profit Ratio | 24.18% | 22.94% | 23.03% | 34.97% | 33.85% | 27.04% | 24.51% | 21.29% |
| Research & Development | 124.28M | 99.71M | 84.23M | 65.03M | 53.79M | 43.92M | 28.12M | 21.65M |
| General & Administrative | 23.34M | 22.44M | 20.71M | 17.55M | 17.37M | 13.89M | 13.62M | 37.83M |
| Selling & Marketing | 23.01M | 35.80M | 27.76M | 18.44M | 104.79M | 74.32M | 68.88M | 45.58M |
| SG&A | 127.85M | 58.25M | 48.47M | 35.99M | 122.16M | 88.21M | 82.49M | 83.41M |
| Other Expenses | -7.40M | 39.42M | 23.38M | 14.63M | 39.14M | -29.80K | 1.29M | 2.74M |
| Operating Expenses | 245.83M | 197.38M | 156.09M | 115.65M | 215.09M | 160.16M | 142.55M | 110.46M |
| Cost & Expenses | 2.36B | 1.89B | 1.38B | 973.83M | 1.21B | 1.18B | 840.59M | 711.30M |
| Interest Income | 21.21M | 15.59M | 6.32M | 2.26M | 2.81M | 764.80K | 783.09K | 4.00M |
| Interest Expense | 37.15M | 14.24M | 3.90M | 8.44M | 12.15M | 14.97M | 15.30M | 19.97M |
| Depreciation & Amortization | 172.84M | 113.31M | 91.24M | 65.73M | 55.63M | 51.83M | 48.19M | 47.44M |
| EBITDA | 630.76M | 463.50M | 343.19M | 415.65M | 350.53M | 275.69M | 124.65M | 102.81M |
| EBITDA Ratio | 22.67% | 21.44% | 21.86% | 31.50% | 24.75% | 20.95% | 13.58% | 13.62% |
| Operating Income | 427.09M | 349.23M | 256.64M | 356.11M | 310.53M | 224.31M | 62.80M | 31.11M |
| Operating Income Ratio | 15.35% | 15.87% | 16.10% | 26.99% | 20.55% | 16.02% | 6.79% | 4.08% |
| Total Other Income/Expenses | -4.68M | -6.45M | -2.57M | -7.60M | -2.48M | 328.61K | 1.29M | 2.74M |
| Income Before Tax | 422.40M | 342.78M | 254.07M | 348.52M | 308.05M | 224.64M | 64.09M | 33.85M |
| Income Before Tax Ratio | 15.18% | 15.58% | 15.94% | 26.41% | 20.39% | 16.05% | 6.93% | 4.43% |
| Income Tax Expense | 50.02M | 23.50M | 17.36M | 41.35M | 37.94M | 25.26M | 8.16M | 5.14M |
| Net Income | 371.45M | 319.28M | 236.71M | 307.17M | 270.11M | 199.38M | 55.94M | 28.71M |
| Net Income Ratio | 13.35% | 14.51% | 14.85% | 23.28% | 17.88% | 14.24% | 6.05% | 3.76% |
| EPS | 1.63 | 1.40 | 1.04 | 1.34 | 1.18 | 1.21 | 0.38 | 0.19 |
| EPS Diluted | 1.63 | 1.40 | 1.04 | 1.34 | 1.18 | 1.21 | 0.38 | 0.19 |
| Weighted Avg Shares Out | 228.46M | 228.46M | 228.46M | 228.46M | 228.46M | 164.89M | 146.19M | 148.07M |
| Weighted Avg Shares Out (Dil) | 228.46M | 228.46M | 228.46M | 228.46M | 228.46M | 164.89M | 146.19M | 148.09M |
Source: https://incomestatements.info
Category: Stock Reports